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Progression-free survival (PFS) and overall survival (OS) were 
estimated by the Kaplan–Meier method. Cox regression was 
performed to explore parameters in association with PFS and 
OS. The potential variables that were examined included age; 
gender; primary site; UICC stages; serum albumin, C-reactive 
protein (CRP), albumin–globulin ratio, body weight (BW) and 
body mass index prior to treatment; initial CBV and GTV; 
GTVRR during EBRT; IC; and CC. 
 
Results: The median follow-up period was 23 months (range, 
2–95 months). The 2-year PFS and OS rates were 51.3% [95% 
confidence interval (CI), 40.2–55.7] and 71.0% (95% CI, 58.4–
72.6), respectively. PFS was associated with age [hazard ratio 
(HR): 1.029 (95% CI, 1.001–1.058), p = 0.04]; stage IV disease 
[HR: 3.755 (95% CI, 1.810–7.788), p < 0.001]; pretreatment 
CRP [HR: 1.077 (95% CI, 1.008–1.152) p = 0.029]; initial GTV 
[HR: 1.004 (95% CI, 1.000–1.007), p = 0.026]; and GTVRR 
during EBRT [HR: 0.99 (95% CI, 0.982–0.998), p = 0.016]. OS 
was related to stage IV disease [HR: 3.669 (95% CI, 1.667–
8.071), p = 0.001]; GTVRR during EBRT [HR: 0.986 (95% CI, 
0.975–0.997), p = 0.012]; and pretreatment BW [HR: 0.927 
(95% CI, 0.892–0.963), p < 0.001]. 
 
Conclusion: This study suggested the prognostic value of 
clinical and volumetric status. Clinical stage, age, 
pretreatment CRP and BW, initial GTV, and shrinkage of GTV 
during treatment appear to be critical in the HNC treatment 
strategy. 
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Purpose or Objective: Head and neck cancer patients 
suffered from swallowing and speaking difficulties, neck pain 
and stiffness, and cosmetic disfigurement, resulting in 
interpersonal relationship troubles and social and emotional 
adaptation issues. Discussing cancer and the quality of 
communication when facing stress would affect partner’s 
adaptation to cancer and quality of relationship. This study 
investigated the (Cancer-related) communication pattern, 
effect of disease characteristics in head and neck cancer. We 
used dyadic analysis to investigate the impact and process of 
communication pattern on quality of relationship. 
 
Material and Methods: This study is cross-sectional design, 
and subject were the male patients who completion of 
cancer treatment more than 3 months and their partners with 
head and neck cancer, included 131 patient-partner dyads. 
Each participant completed the basic information 
questionnaire, Communication Pattern Questionnaire, Dyadic 
and Adjustment Scale. 
 
Results: By treatment, there are no difference on cancer-
related communication pattern for both patient and partner. 
Both patient and partner, their perception of mutual 
constructive communication was associated with more 
quality of relationship, Demand-withdraw communication and 
mutual avoidancewas associated with less quality of 
relationship. Using the Actor-Partner interdependence model 
(APIM), result reveled that although each person’s cancer-
related communication pattern is the strongest predictor of 
their own quality of relationship, partner’s perception of 
communication pattern also play significant role on patient’s 
quality of relationship. According to APIM, only the partner 
perceived communication pattern could be accounted for by 
their influence on quality of relationship. 
 
Conclusion: We found that cancer-related communication 
and interaction of relationship among couples play an 
important role in the head and neck adjustment process. 
Thus, except the medical care, clinicians concern with 
interaction between patient and partner can be enhance 
their psychological adjustment and illness, particularly the 
partner’s perception of communication pattern, which may 
improve the quality of relationship and life adaptation of 
both couples when they are dealing with head and neck 
cancer. 
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Purpose or Objective: Reducing overall treatment time has 
advantages for patient convenience, but also for local control 
as shown by former studies. Critical organs in the neck causes 
concern in relation to long-term morbidity and quality of life, 
but with recent advances with high-precision image-guided 
and intensity-modulated radiotherapy (IMRT) techniques, 
avoidance of the organs at risk has become possible. The 
purpose of this study is to develop an image-guided high-dose 
hypofractionated vocal cord irradiation technique to treat 
patients with early stage glottic cancer. 
 
Material and Methods: Eligible patients with early stage 
glottic cancer provided with informed consent will receive 
hypofrationated radiotherapy to the larynx with a 
simultaneous boost to the gross tumor. The fraction size will 
be stepwise increased from 3.5Gy (total dose 59.4Gy) to 9Gy 
(total dose 45Gy). To proceed to the next dose level, at least 
7 patients should be confirmed that they have no toxicity 
more than grade 2 after 3 month post-RT. The organs at risk 
include the larynx, contralateral vocal cord, arytenoids, 
carotid arteries, inferior pharyngeal constrictor muscle, and 
spinal cord. 
 
Results: Four patients were enrolled to receive 59.4Gy with 
3.5Gy per fraction until July 2015. None of the patients 
developed toxicity more than grade 2 after 1 month post-RT. 
The mean equivalent dose in 2Gy fractions (EQD2) to 
contralateral arytenoid, thyroid gland, inferior pharyngeal 
constrictor muscle, and larynx were in average 69.5Gy, 
12.3Gy, 50.8Gy, and 66.5Gy, respectively. No portion of the 
carotid arteries were irradiated more than 50 Gy (EQD2) in 
the IMRT plan. After 3 months of follow-up, all 4 patients 
demonstrated no more than grade 3 toxicities. Also, all 
patients showed complete remission by laryngoscopy. 
 
Conclusion: The high-dose hypofractionated IMRT technique 
provided good sparing of critical structures and resulted in no 
severe toxicity after a short term follow up. We will 
continuously perform this phase I clinical trial to stepwise 
increase the fraction size up to 9Gy. 
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Purpose or Objective: 
Objective: The aim of this study was to investigate the 
feasibility of high dose-low energy intraoperative radiation 
(IORT) therapy using INTRABEAM© (Carl Zeiss Surgical, 
Oberkochen, Germany) in the treatment of malignant Head & 
Neck tumors.  
 
Methods and Materials: Between March 2014 and July 2015, 
12 patients with head and neck cancers (seven with primary 
malignant parotid tumors and five patients with previously 
treated recurrent head and neck cancer) received 
intraoperative radiation therapy after surgical resection at 
Loyola University Medical Center (Maywood, IL). The median 
dose prescription was 6Gy (range, 5-14Gy) prescribed to 5mm 
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depth in a single fraction delivered with cylindrical shaped 
flat applicators attached to a 50kV x-ray energy source 
(INTRABEAM). The flat applicator (sizes 3-6cm) was placed at 
the high-risk area within the surgical cavity, which was 
delineated by the surgeon as the area with high likelihood for 
close or positive margins. The average IORT delivery time was 
20 minutes. The single IORT fraction was the sole treatment 
for all patients with recurrent, previously treated patients 
and in one patient with parotid tumors, while the remaining 
six patients with parotid malignancies received additional 
external beam radiotherapy(EBRT) (median dose 50Gy) four 
weeks after surgery. Decision for EBRT were based on review 
of final pathology. 
 
Results: All patients underwent successful completion of 
intraoperative radiotherapy. With follow up time of 5 to 18 
months, there have been no acute side effects or 
complications related to IORT. All patients with parotid 
tumors are currently NED; in patients with recurrent tumors, 
1 of 5 has re-recurred. 
 
Conclusion: IORT with low kv x-rays appears to be an 
excellent choice for selected patients with H&N cancers, 
both primary(parotid) and recurrent disease.  
We are now in the process of initiating a prospective trial 
evaluating the use of IORT as part of primary management of 
parotid tumors at our institution.  
Detailed results will be presented. 
 
Corresponding author: 
Emami, M.D, FACR, FASTRO Professor  
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Purpose or Objective: Patients treated with concurrent 
chemoradiation (CCRT) for head and neck cancer (HNC) with 
HPV(+) associated tumours have a significantly better 
prognosis compared to those with HPV(-) tumours. Similarly, 
better prognosis was associated with changes during-
treatment consisting of either a reduction in tumour volume, 
or FDG-PET SUV, or an increase in ADC. This study 
investigated a possible association between these imaging 
biomarkers and HPV status. Our hypothesis was that HPV(+) 
tumours show a stronger ADC increase and a larger volume 
and SUV decrease. 
 
Material and Methods: 13 Patients with HNC stadium III-IVA 
underwent CCRT (11 oropharynx, 1 hypopharynx and 1 oral 
cavity). HPV status was assessed using P16 staining. Patients 
received FDG-PET and MRI imaging before the start of the 
treatment and at the end of the second week. The region of 
interest consisted of the GTV and was delineated by 
dedicated radiation-oncologists. The volume and the median 
SUV and ADC were measured pretreatment and during 
treatment. Relative responses were calculated by subtracting 
the pretreatment from the during treatment value, which 
was then normalized to the pretreatment value. A new 
variable (pooled response) was computed consisting of the 
average of the relative SUV and volume decrease and ADC 
increase. A one tailed independent samples t-test compared 
the average responses between the HPV(+) and HPV(-) 
tumours. Voxel-based Pearson correlation coefficients 
between baseline and response maps were calculated for ADC 
and FDG-PET. A Fisher’s z-transformation was used to 
compare the correlation coefficients between HPV(+) and 
HPV(-) tumours. 
 
Results: 7 out of 13 tumours were HPV(+) and 6 HPV(-). 
Comparing HPV(+) to HPV(-), GTV volume decreased 42% vs 
28% (p=0.080), SUV decreased with 32% vs 5% for (p=0.074) 
and ADC increased 24% vs 7% (p=0.058) (figure 1). The total 
response was significantly higher for HPV(+) tumours (33% vs 
13%, p=0.012). Correlation coefficients between baseline and 
response maps did not differ significantly for HPV(+) and 
HPV(-) tumours (PET: z= 1.05 vs 1.08 p=0.85, ADC: z=0.47 vs 
0.51, p=0.78). 
 
Conclusion: Volume, ADC and FDG-PET individually showed a 
trend towards a higher response in the HPV(+) tumours at the 
end of the second week CCRT. The total response was 
significantly higher for HPV(+) tumours, demonstrating a 
significant association between HPV-status and imaging 
biomarkers. The similar correlation coefficients of the 
response maps indicate the spatial distribution does not 
depend on HPV status. This study emphasises the importance 
of reporting HPV status in imaging response biomarker studies 
for HNC patients. A validation of the prognostic value of 
imaging response biomarkers within HPV(+) and (-) cohorts is 
warranted. 
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Purpose or Objective: MTL005 is a novel metalloporphyrin 
that demonstrated efficacy as a radiosensitizer in oxic and 
hypoxic pre-clinical models, increasing tumour doubling times 
by 50-90% depending on radiation dose. MTL005 achieved 
higher concentrations in tumour tissue compared with normal 
tissues (6:1 ratio), and these higher levels were retained for 
up to 62 days post administration. We developed a first-in-
human phase I, open label, dose escalation, multicenter 
clinical trial to evaluate the safety and tolerability of single 
dose MTL005 in combination with radiotherapy (Part 1) and 
cisplatin chemo-radiotherapy (Part 2) in patients with locally 
advanced head & neck cancer treated with palliative and 
curative intent respectively. The results of Part 1 of the 
study are reported. 
 
Material and Methods: In Part 1 of the study MTL005 was 
administered 1 week prior to palliative radiotherapy as i.v. 
injection in 38-76 minutes. Two dose levels were explored (2 
and 4 mg/kg). Patients were immobilised in a thermoplastic 
mask and a contrast enhanced CT scan was used to define the 
PTV and the organs at risk. Radiotherapy was delivered with 
IMRT with a total dose of 50Gy to the PTV in 25 consecutive 
